The Moderna Vaccine IndexThese companies are selected for composition "Moderna Vaccine" because
1.developed the vaccine
2.suppliers
3.distribution chain
Weights are calculated by relative market cap.
3.69EUR
199.67 MEUR
817.70 MEUR
18.48 M
About LABORATORIOS FARMACEUT.
Sector
CEO
Juan López-Belmonte Encina
Headquarters
Madrid
Website
Employees (FY)
1.99 K
Founded
1946
ISIN
ES0157261019
FIGI
BBG000RL1KN2
Laboratorios Farmaceúticos Rovi SA engages in the research, development, manufacture, and marketing of small molecule and specialty biologic drugs. It operates through the following business segments: Manufacturing, Marketing, and Other. The Manufacturing segment obtains its income from service contracts that relate to the finalization of the pharmaceutical product production process for external entities and the manufacture of products to be subsequently marketed by other group companies. The Marketing segment purchases and sells pharmaceutical products. The Other segment includes other services, research, and development activities that are not significant for the group. The company was founded on December 21, 1946 and is headquartered in Madrid, Spain.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on MUN exchange LABORATORIOS FARMACEUT. stocks are traded under the ticker 41L.
LABORATORIOS FARMACEUT. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for LABORATORIOS FARMACEUT. has a max estimate of 93.00 EUR and a min estimate of 60.00 EUR.
41L earnings for the last quarter are 0.15 EUR whereas the estimation was 0.11 EUR which accounts for 36.36% surprise. Estimated earnings for the next quarter are 0.61 EUR. See more details about LABORATORIOS FARMACEUT. earnings.
LABORATORIOS FARMACEUT. revenue for the last quarter amounts to 214.05 M EUR despite the estimated figure of 210.56 M EUR. In the next quarter revenue is expected to reach 223.60 M EUR.
Yes, you can track LABORATORIOS FARMACEUT. financials in yearly and quarterly reports right on TradingView.
41L net income for the last quarter is 52.18 M EUR, while the quarter before that showed 19.19 M EUR of net income which accounts for 171.96% change. Track more LABORATORIOS FARMACEUT. financial stats to get the full picture.
Yes, 41L dividends are paid annually. The last dividend per share was 1.05 EUR. As of today, Dividend Yield (TTM)% is 1.32%. Tracking LABORATORIOS FARMACEUT. dividends might help you take more informed decisions.
LABORATORIOS FARMACEUT. dividend yield was 2.91% in 2022, and payout ratio reached 28.06%. The year before the numbers were 1.05% and 28.02% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, 41L shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade LABORATORIOS FARMACEUT. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 1.99 K employees. See our rating of the largest employees — is LABORATORIOS FARMACEUT. on this list?
We've gathered analysts' opinions on LABORATORIOS FARMACEUT. future price: according to them, 41L price has a max estimate of 93.00 EUR and a min estimate of 60.00 EUR. Read a more detailed LABORATORIOS FARMACEUT. forecast: see what analysts think of LABORATORIOS FARMACEUT. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. LABORATORIOS FARMACEUT. EBITDA is 275.25 M EUR, and current EBITDA margin is 33.83%. See more stats in LABORATORIOS FARMACEUT. financial statements.